Sanofi Stock Other OTC
Stocks
SNYNF
FR0000120578
Pharmaceuticals
OTC Markets Traded| Market Cap | 93.51B 106B 87.1B 79.97B 150B 10,199B 152B 1,034B 404B 5,039B 399B 391B 17,407B | P/E 2026 * |
11.7x | P/E 2027 * | 10.8x |
|---|---|---|---|---|---|
| Enterprise Value | 103B 117B 96.23B 88.35B 166B 11,268B 168B 1,143B 446B 5,567B 441B 431B 19,232B | EV / Sales 2026 * |
2.19x | EV / Sales 2027 * | 1.98x |
| Free-Float |
89% | Yield 2026 * |
5.47% | Yield 2027 * | 5.79% |
Last Transcript: Sanofi
| 1 day | -1.88% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 2023-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 57 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 64 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.88% | -.--% | - | - | 104B | |
| +0.13% | +1.56% | +47.35% | +164.01% | 1,067B | |
| +0.97% | +5.10% | +58.02% | +53.98% | 635B | |
| -0.94% | +0.95% | +35.02% | +81.05% | 458B | |
| +1.41% | +7.75% | +38.93% | +32.88% | 347B | |
| +1.28% | +2.82% | +38.42% | +43.21% | 295B | |
| +1.72% | +2.33% | +19.31% | +20.79% | 262B | |
| +1.84% | -1.03% | -27.78% | -38.45% | 216B | |
| +0.06% | +2.72% | +22.73% | +59.97% | 203B | |
| +0.94% | -2.80% | +12.32% | +69.09% | 161B | |
| Average | +0.53% | +1.33% | +27.15% | +54.06% | 404.83B | |
| Weighted average by Cap. | +0.47% | +1.95% | +36.75% | +79.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.15B 53.61B 43.92B 40.32B 75.71B 5,143B 76.68B 522B 204B 2,541B 201B 197B 8,777B | 50.34B 57.23B 46.88B 43.04B 80.82B 5,490B 81.86B 557B 218B 2,712B 215B 210B 9,370B |
| Net income | 8.44B 9.59B 7.86B 7.21B 13.55B 920B 13.72B 93.31B 36.46B 455B 36B 35.23B 1,570B | 9.44B 10.73B 8.79B 8.07B 15.15B 1,029B 15.35B 104B 40.78B 508B 40.27B 39.41B 1,757B |
| Net Debt | 9.8B 11.15B 9.13B 8.38B 15.74B 1,069B 15.94B 108B 42.36B 528B 41.83B 40.94B 1,825B | 6.15B 6.99B 5.72B 5.25B 9.87B 670B 9.99B 67.97B 26.56B 331B 26.22B 25.66B 1,144B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
